Travere Therapeutics (TVTX) to Release Quarterly Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.58) per share and revenue of $72.38 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Travere Therapeutics Stock Performance

Shares of NASDAQ:TVTX opened at $22.66 on Wednesday. The business’s fifty day moving average price is $19.38 and its two-hundred day moving average price is $16.38. Travere Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $25.29. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -4.98 and a beta of 0.72. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Insider Activity

In other news, CFO Christopher R. Cline sold 5,192 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $20.12, for a total transaction of $104,463.04. Following the transaction, the chief financial officer now owns 90,038 shares of the company’s stock, valued at $1,811,564.56. This represents a 5.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Sandra Calvin sold 12,090 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.30, for a total value of $221,247.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares in the company, valued at $1,005,164.10. This trade represents a 18.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 218,425 shares of company stock valued at $4,674,259 over the last 90 days. 3.75% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on TVTX shares. HC Wainwright upped their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, January 15th. Canaccord Genuity Group upped their price target on Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald started coverage on Travere Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating on the stock. Barclays upped their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Finally, Scotiabank upped their price target on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.77.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.